PMID- 31809318
OWN - NLM
STAT- MEDLINE
DCOM- 20200709
LR  - 20200709
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Print)
IS  - 0366-6999 (Linking)
VI  - 132
IP  - 24
DP  - 2019 Dec 20
TI  - Association of leukocyte telomere length with non-alcoholic fatty liver disease 
      in patients with type 2 diabetes.
PG  - 2927-2933
LID - 10.1097/CM9.0000000000000559 [doi]
LID - 2927-2933
AB  - BACKGROUND: Leukocyte telomere has been shown to be related to insulin 
      resistance-related diseases, such as type 2 diabetes mellitus (T2DM) and 
      non-alcoholic fatty liver disease (NAFLD). This cross-sectional study 
      investigated the association of leukocyte telomere length (LTL) with NAFLD in 
      T2DM patients. METHODS: Clinical features were collected and LTL was measured by 
      Southern blot-based terminal restriction fragment length analysis in 120 T2DM 
      patients without NAFLD and 120 age-matched T2DM patients with NAFLD. NAFLD was 
      clinically defined by manifestations of ultrasonography. The correlation between 
      LTL and clinical and biochemical parameters were analyzed by Pearson correlation 
      or Spearman correlation analysis. Factors for NAFLD in T2DM patients were 
      identified using multiple logistic regressions. RESULTS: LTL in T2DM patients 
      with NAFLD were significantly longer than those without NAFLD (6400.2 +/- 71.8 base 
      pairs [bp] vs. 6023.7 +/- 49.5 bp, P < 0.001), especially when diabetes duration 
      was less than 2 years. Meanwhile, the trend of shorter LTL was associated with 
      the increased diabetes duration in T2DM patient with NAFLD, but not in T2DM 
      patients without NAFLD. Finally, LTL (odds ratio [OR]: 1.001, 95% confidence 
      interval [CI]: 1.000-1.002, P = 0.001), as well as body mass index (OR: 1.314, 
      95% CI: 1.169-1.477, P < 0.001) and triglycerides (OR: 1.984, 95% CI: 
      1.432-2.747, P < 0.001), had a significant association with NAFLD status in T2DM 
      patients. CONCLUSIONS: T2DM patients with NAFLD had a significantly longer LTL 
      than those without NAFLD. The longer LTL was especially evident in the early 
      stage of T2DM, indicating that longer LTL may be used as a biomarker for NAFLD in 
      T2DM patients.
FAU - Zhang, Min
AU  - Zhang M
AD  - Hubei Medical Evaluation and Continuing Education Office, Wuhan, Hubei 430000, 
      China.
AD  - Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei 430000, China.
FAU - Hu, Man-Li
AU  - Hu ML
AD  - Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei 430000, China.
AD  - Department of Endocrinology, Wuhan Fourth Hospital, Tongji Medical College, 
      Huazhong University of Science and Technology, Wuhan, Hubei 430000, China.
FAU - Huang, Jiao-Jiao
AU  - Huang JJ
AD  - Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei 430000, China.
FAU - Xia, San-Shan
AU  - Xia SS
AD  - Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei 430000, China.
FAU - Yang, Yan
AU  - Yang Y
AD  - Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei 430000, China.
FAU - Dong, Kun
AU  - Dong K
AD  - Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei 430000, China.
LA  - eng
PT  - Journal Article
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
SB  - IM
MH  - Adult
MH  - Aged
MH  - Cross-Sectional Studies
MH  - Diabetes Mellitus, Type 2/*genetics
MH  - Female
MH  - Humans
MH  - Leukocytes/*metabolism
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Non-alcoholic Fatty Liver Disease/*genetics
MH  - *Telomere
PMC - PMC6964937
EDAT- 2019/12/07 06:00
MHDA- 2020/07/10 06:00
PMCR- 2019/12/20
CRDT- 2019/12/07 06:00
PHST- 2019/12/07 06:00 [pubmed]
PHST- 2020/07/10 06:00 [medline]
PHST- 2019/12/07 06:00 [entrez]
PHST- 2019/12/20 00:00 [pmc-release]
AID - CMJ-2019-1531 [pii]
AID - 10.1097/CM9.0000000000000559 [doi]
PST - ppublish
SO  - Chin Med J (Engl). 2019 Dec 20;132(24):2927-2933. doi: 
      10.1097/CM9.0000000000000559.